Amphastar Pharmaceuticals Inc (AMPH) Return on Equity ROE from the second quarter 2026 to second quarter 2025 and annually, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Amphastar Pharmaceuticals Inc   (NASDAQ: AMPH)

Amphastar Pharmaceuticals Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Amphastar Pharmaceuticals Inc in the second quarter 2026?
Amphastar Pharmaceuticals Inc achieved a return on average equity (ROE) of 10.11 % in its second quarter 2026, this is above AMPH's average return on equity of 8.65%.
Amphastar Pharmaceuticals Inc shareholder's equity over the 12 months ending in its second quarter 2026 are valued at $777 million

ROE fell compared to the first quarter 2026, despite the net income growth of 372.71% from the first quarter 2026.

Within the Major Pharmaceutical Preparations industry 53 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2026 from 1300 to 1392.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Equity Change 1.41 % 2.94 % 7.72 % 6.74 % -
Y / Y Net Income Change -2.2 % -74.61 % -35.65 % -57.09 % -18.23 %
Net Income (TTM) in Millions 79 79 98 112 135
Return On Equity (TTM) 10.11 % 10.23 % 12.76 % 14.8 % 18.15 %
AMPH's Total Ranking # 1392 # 1300 # 842 # 541 # 696
Equity (TTM) in Millions 768 773 789 777 757
Seq. Equity Change -0.68 % -1.95 % 1.55 % 2.54 % 0.83 %
Seq. Net Income Change 372.71 % -73.72 % 40.8 % -44.09 % 22.72 %

Back to AMPH Management Effectiveness >> AMPH's 5 Years Annual ROE >> Compare AMPH ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 54
Sector # 141
Overall # 1392

Return On Equity Statistics
High Average Low
25.42 %
8.65 %
-5.39 %
(Jun 30 2024)   (Jun 30 2015)





AMPH Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Equity in Millions 789 732 639 529 446
Y / Y Equity Change 7.72 % 14.53 % 20.95 % 18.66 % -0.71 %
Net Income in Millions 98 160 138 91 63
Y / Y Net Income Change -38.51 % 15.98 % 50.51 % 44.37 % 5670.37 %
Return On Equity 12.44 % 21.78 % 21.51 % 17.29 % 14.21 %

Back to AMPH Management Effectiveness >> AMPH's 5 Years Annual ROE >> Compare AMPH ROE to its Competitors




Annual Roe Comment
In 2025 ROE decreased compared to the previous year to 12.44 %, due to deterioration of net income.


More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
AMPH's' Return on Equity at Yahoo Finance
AMPH's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for AMPH's Competitors
Subscribers only: Roe for Amphastar Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Equity for AMPH's Customers




Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector ROE
Pacs Group Inc   27.00 %
Sotera Health Company  26.75 %
Insulet Corporation  26.69 %
Bioventus Inc   25.96 %
Johnson and Johnson  25.74 %
Encompass Health Corporation  25.52 %
Resmed Inc   24.21 %
Healthcare Services Group Inc   24.12 %
Electromed Inc   23.65 %
Iradimed Corporation  23.45 %
Vertex Pharmaceuticals Inc  23.31 %
Lantheus Holdings Inc   23.27 %
Msa Safety Inc  23.15 %
Prestige Consumer Healthcare Inc   21.77 %
Jazz Pharmaceuticals Plc  21.37 %
Neurocrine Biosciences Inc   21.13 %
Universal Health Services Inc   20.89 %
Puma Biotechnology Inc   20.85 %
Entera Bio Ltd   20.82 %
United Therapeutics Corporation  20.18 %
Ligand Pharmaceuticals Incorporated  20.06 %
Harmony Biosciences Holdings inc   20.06 %
Pediatrix Medical Group Inc   19.89 %
Theravance Biopharma inc   19.40 %
Krystal Biotech Inc   19.34 %
Ani Pharmaceuticals Inc  19.33 %
Brightspring Health Services Inc   18.93 %
Sbc Medical Group Holdings Incorporated  18.69 %
West Pharmaceutical Services Inc   18.51 %
Intuitive Surgical Inc   17.82 %

Date modified: 2026-09-08T01:08:10+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.